Jacqueline Lammert1, Jan Lubinski2, Jacek Gronwald2, Tomasz Huzarski2, Susan Armel3, Andrea Eisen4, Wendy S Meschino5, Henry T Lynch6, Carrie Snyder6, Charis Eng7, Olufunmilayo I Olopade8, Ophira Ginsburg9, William D Foulkes10, Christine Elser11, Stephanie A Cohen12, Marion Kiechle1, Steven A Narod13,14, Joanne Kotsopoulos15,16. 1. Department of Gynecology and Center for Hereditary Breast and Ovarian Cancer, University Hospital rechts der Isar, Technical University of Munich (TUM), Munich, Germany. 2. International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland. 3. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Toronto, Toronto, ON, Canada. 4. Toronto-Sunnybrook Regional Cancer Center, Toronto, ON, Canada. 5. North York General Hospital, Toronto, ON, Canada. 6. Creighton's Hereditary Cancer Center, Creighton University School of Medicine, Omaha, NE, USA. 7. Cleveland Clinic, Genomic Medicine Institute and Center for Personalized Genetic Healthcare, Cleveland, OH, USA. 8. Department of Medicine, University of Chicago, Chicago, IL, USA. 9. Langone Health and Department of Population Health, NYU School of Medicine, Perlmutter Cancer Center, New York University (NYU), New York, NY, USA. 10. Program in Cancer Genetics, Department of Oncology and Human Genetics, McGill University, Montréal, QC, Canada. 11. Division of Medical Oncology and Hematology, Department of Medicine, Mount Sinai Hospital and The Princess Margaret Cancer Center, Toronto, ON, Canada. 12. Cancer Genetics Risk Assessment Program, St. Vincent Health, Indianapolis, IN, USA. 13. Women's College Research Institute, Women's College Hospital, 76 Grenville St., 6th Floor, Toronto, ON, M5S 1B2, Canada. 14. Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. 15. Women's College Research Institute, Women's College Hospital, 76 Grenville St., 6th Floor, Toronto, ON, M5S 1B2, Canada. joanne.kotsopoulos@wchospital.ca. 16. Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. joanne.kotsopoulos@wchospital.ca.
Abstract
BACKGROUND: Physical activity is inversely associated with the risk of breast cancer among women in the general population. It is not clear whether or not physical activity is associated with the risk of BRCA-associated breast cancer. METHODS: We conducted a case-control study of 443 matched pairs of BRCA mutation carriers to evaluate the association between physical activity and breast cancer risk. Moderate and vigorous physical activities at ages 12-13, ages 14-17, ages 18-22, ages 23-29 and ages 30-34 were determined using the Nurses' Health Study II Physical Activity Questionnaire. We estimated mean metabolic equivalent task hours/week for moderate, vigorous and total physical activities overall (ages 12-34), during adolescence (ages 12-17) and during early adulthood (ages 18-34). Logistic regression analysis was used to estimate the odds ratios (OR) and 95% confidence intervals (CI) for total, moderate and strenuous recreational physical activities and breast cancer risk, by menopausal status. RESULTS: Overall, there was no significant association between total physical activity and subsequent breast cancer risk (ORQ4 vs. Q1 = 1.01, 95% CI 0.69-1.47; P-trend = 0.72). Moderate physical activity between ages 12-17 was associated with a 38% decreased risk of premenopausal breast cancer (ORQ4 vs. Q1 = 0.62; 95% CI 0.40-0.96; P-trend = 0.01). We found no association between exercise and breast cancer diagnosed after menopause. CONCLUSIONS: These findings suggest that early-life physical activity is associated with a reduced risk of premenopausal breast cancer among BRCA mutation carriers. IMPACT: Future prospective analyses, complemented by mechanistic evidence, are warranted in this high-risk population.
BACKGROUND: Physical activity is inversely associated with the risk of breast cancer among women in the general population. It is not clear whether or not physical activity is associated with the risk of BRCA-associated breast cancer. METHODS: We conducted a case-control study of 443 matched pairs of BRCA mutation carriers to evaluate the association between physical activity and breast cancer risk. Moderate and vigorous physical activities at ages 12-13, ages 14-17, ages 18-22, ages 23-29 and ages 30-34 were determined using the Nurses' Health Study II Physical Activity Questionnaire. We estimated mean metabolic equivalent task hours/week for moderate, vigorous and total physical activities overall (ages 12-34), during adolescence (ages 12-17) and during early adulthood (ages 18-34). Logistic regression analysis was used to estimate the odds ratios (OR) and 95% confidence intervals (CI) for total, moderate and strenuous recreational physical activities and breast cancer risk, by menopausal status. RESULTS: Overall, there was no significant association between total physical activity and subsequent breast cancer risk (ORQ4 vs. Q1 = 1.01, 95% CI 0.69-1.47; P-trend = 0.72). Moderate physical activity between ages 12-17 was associated with a 38% decreased risk of premenopausal breast cancer (ORQ4 vs. Q1 = 0.62; 95% CI 0.40-0.96; P-trend = 0.01). We found no association between exercise and breast cancer diagnosed after menopause. CONCLUSIONS: These findings suggest that early-life physical activity is associated with a reduced risk of premenopausal breast cancer among BRCA mutation carriers. IMPACT: Future prospective analyses, complemented by mechanistic evidence, are warranted in this high-risk population.
Entities:
Keywords:
BRCA1; BRCA2; Breast cancer; Exercise; Physical activity
Authors: Jeremy S Haley; Elizabeth A Hibler; Shouhao Zhou; Kathryn H Schmitz; Kathleen M Sturgeon Journal: Cancer Date: 2019-09-30 Impact factor: 6.860
Authors: Rebecca D Kehm; Jeanine M Genkinger; Robert J MacInnis; Esther M John; Kelly-Anne Phillips; Gillian S Dite; Roger L Milne; Nur Zeinomar; Yuyan Liao; Julia A Knight; Melissa C Southey; Wendy K Chung; Graham G Giles; Sue-Anne McLachlan; Kristen D Whitaker; Michael Friedlander; Prue C Weideman; Gord Glendon; Stephanie Nesci; kConFab Investigators; Irene L Andrulis; Saundra S Buys; Mary B Daly; John L Hopper; Mary Beth Terry Journal: Cancer Res Date: 2019-10-02 Impact factor: 12.701
Authors: Adriana M Coletta; Susan K Peterson; Leticia A Gatus; Kate J Krause; Susan M Schembre; Susan C Gilchrist; Banu Arun; Y Nancy You; Miguel A Rodriguez-Bigas; Larkin L Strong; Karen H Lu; Karen Basen-Engquist Journal: Hered Cancer Clin Pract Date: 2020-03-07 Impact factor: 2.857
Authors: A Berling-Ernst; M Yahiaoui-Doktor; M Siniatchkin; M Halle; M Kiechle; C Engel; J Lammert; S Grill; R Dukatz; K Rhiem; F T Baumann; S C Bischoff; N Erickson; T Schmidt; U Niederberger Journal: Sci Rep Date: 2022-02-21 Impact factor: 4.379
Authors: Daniel A Bizjak; Sebastian V W Schulz; Uwe Schumann; Stephanie Otto; Johannes Kirsten; Florian Ebner; Elena Leinert; Jens Huober; Wolfgang Janni; Jürgen Michael Steinacker Journal: Cancers (Basel) Date: 2020-06-10 Impact factor: 6.639